

## Concerto HealthAI collaborates with Pfizer for precision oncology

10 April 2019 | News

### Integration of Concerto HealthAI's Real-World Data and Advanced AI Capabilities Will Accelerate Patient Insights and Outcomes Studies



Concerto HealthAI has announced that they have entered into a collaboration with Pfizer to advance work in Precision Oncology using Concerto HealthAI's eurekaHealth platform, artificial intelligence (AI) models and Real World Clinical Electronic Medical Record (EMR) and healthcare claims.

Data from clinical practices participating in the American Society of Clinical Oncology's CancerLinQ® initiative and others throughout the U.S. will be utilized for the collaboration and is one of the most comprehensive Real World Data (RWD) sets available. The collaboration's goal is to quicken the pace for actionable patient insights for Pfizer's investigational therapies and commercialized therapeutics used in the treatment of solid tumors and hematologic malignancies.

Chris Boshoff, Chief Development Officer, Oncology, Pfizer Global Product Development said, "Pfizer believes real-world data have tremendous potential to inform how we develop and use medicines to improve patient outcomes. We are pleased to work with Concerto HealthAI — to accelerate insights and outcomes studies that may lead to a more comprehensive understanding of patients' experience with our medicines."

Jeff Elton, CEO of Concerto HealthAI said, "This collaboration aims to find and help patients who may benefit from new therapeutic combinations. We are using our definitive real-world data, AI-enabled abstraction, data science expertise, and strength in outcomes research to identify new and more precise treatment options; refine study designs; and speed up the completion times for various outcomes studies."

Romesh Wadhvani, Executive Chairman of Concerto HealthAI said, "The talented individuals of Pfizer and Concerto HealthAI working together, with our eurekaHealth AI platform and real-world data, allows us to go much faster when it comes to finding and acting on meaningful insights in key cancer subpopulations."

The collaboration will conduct novel synthetic control arm and prospective RWD outcomes study designs for therapeutics that are both pre- and post-approval. This builds on work in study designs based on RWD that CancerLinQ, Concerto HealthAI, and others have undertaken in collaboration with the U.S. Food and Drug Administration.

A Concerto HealthAI-Pfizer joint steering committee will oversee the collaboration. The first outcomes research and publications are expected in early 2020.